MLN8237 in Young Patients With Relapsed or Refractory Solid Tumors or Acute Lymphoblastic Leukemia



Status:Archived
Conditions:Cancer, Brain Cancer, Blood Cancer, Leukemia
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:September 2008

Use our guide to learn which trials are right for you!

A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors


RATIONALE: MLN8237 may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth.

PURPOSE: This phase I/II trial is studying the side effects and best dose of MLN8237 and to
see how well it works in treating young patients with relapsed or refractory solid tumors or
acute lymphoblastic leukemia (acute lymphoblastic leukemia closed to accrual as of
02/18/10).


OBJECTIVES:

Primary

- To estimate the maximum tolerated dose and recommended phase II dose of Aurora A kinase
inhibitor MLN8237 administered once daily or twice daily in pediatric patients with
relapsed or refractory solid tumors (except CNS tumors) or acute lymphoblastic leukemia
(ALL). (ALL closed to accrual as of 02/18/10)

- To evaluate the toxicity of this drug in these patients.

- To characterize the pharmacokinetics of this drug in these patients.

Secondary

- To determine the antitumor activity of this drug in these patients. (Phase I)

- To determine the efficacy of this drug, using the once daily dosing schedule, in these
patients. (Phase II)

- To explore the relationship between polymorphic variations in the
UDPglucuronyltransferase gene UGT1A1 and exposure to MLN8237.

- To assess two common polymorphic variants in the Aurora A kinase gene (Phe31Ile and
Val57Ile) thought to potentially influence tumorigenesis.

- To examine the relationship between Aurora A expression status and response to Aurora A
inhibition.

OUTLINE: This is a multicenter phase I, dose escalation followed by a phase II study.
Patients are stratified according to diagnosis (solid tumors vs neuroblastoma vs acute
lymphoblastic leukemia). (Acute lymphoblastic leukemia closed to accrual as of 02/18/10)

Patients receive oral Aurora A kinase inhibitor MLN8237 once or twice daily on days 1-7.
Courses repeat every 21 days for up to 24 months in the absence of disease progression or
unacceptable toxicity.

Whole blood samples are collected from all patients for genotyping for polymorphisms in
UGT1A1 enzymes and polymorphisms in the Aurora A kinase gene. For patients in the phase II
portion of the study, previously preserved tumor tissue blocks and bone marrow or peripheral
blasts are evaluated for Aurora A kinase protein using IHC, mRNA expression, and gene
amplification using FISH or quantitative PCR. Bone marrow is also obtained for FAB
morphology, immunophenotyping, and cytogenetics. Blood samples are also collected
periodically during the first course of therapy for pharmacokinetics studies.


We found this trial at
18
sites
Ann Arbor, MI 48109Bus: -
Ann Arbor, Michigan 48109
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
1802 6th Avenue South
Birmingham, Alabama 35294
(205) 934-4011
UAB Comprehensive Cancer Center One of the nation’s leading cancer research and treatment centers, the...
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
300 Longwood Avenue
Boston, Massachusetts 02115
617-355-6000
Children's Hospital - Boston Boston Children's Hospital is a 395-bed comprehensive center for pediatric health...
?
mi
from
Boston, MA
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
(617) 632-3000
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute Founded in 1997, Dana-Farber/Harvard Cancer Center (DF/HCC) was...
?
mi
from
Boston, MA
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
 1-513-636-4200 
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas From its...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
425 E River Pkwy # 754
Minneapolis, Minnesota 55455
612-624-2620
Masonic Cancer Center at University of Minnesota The Masonic Cancer Center was founded in 1991....
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
3181 SW Sam Jackson Park Rd
Portland, Oregon 97239
(503) 494-5058
Knight Cancer Institute at Oregon Health and Science University Cancer takes many forms. Although cancer...
?
mi
from
Portland, OR
Click here to add this to my saved trials
4800 Sand Point Way Northeast
Seattle, Washington 98105
(206) 987-2000
Children's Hospital and Regional Medical Center - Seattle Seattle Children
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Brooklyn, New York 11203
?
mi
from
Brooklyn, NY
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
1 Baylor Plaza
Houston, Texas 77030
(713) 798-4951
Baylor School of Medicine Baylor College of Medicine is a health sciences university that creates...
?
mi
from
Houston, TX
Click here to add this to my saved trials
Indianapolis, Indiana 46202
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
?
mi
from
Memphis, TN
Click here to add this to my saved trials
722 W 168th St
New York, New York 10032
(212) 305-2500
Columbia Presbyterian Med Ctr On January 1, 1998, The New York Hospital publicly announced its...
?
mi
from
New York, NY
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15213
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
660 S Euclid Ave
St. Louis, Missouri 63110
(800) 600-3606
Siteman Cancer Center The Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University...
?
mi
from
St. Louis, MO
Click here to add this to my saved trials